These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

180 related items for PubMed ID: 1405364

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Pharmacologic treatment of type 2 diabetic dyslipidemia.
    Moon YS, Kashyap ML.
    Pharmacotherapy; 2004 Dec; 24(12):1692-713. PubMed ID: 15585439
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Cholesterol metabolism in glomerular cells: effect of lipoproteins from nephrotic patients.
    Wanner C, Krämer-Guth A, Nauck M, Quaschning T, Pavenstädt H, Schollmeyer P.
    Miner Electrolyte Metab; 1996 Dec; 22(1-3):39-46. PubMed ID: 8676822
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. [Hyperlipidemia in nephrotic syndrome].
    Heaf JG.
    Ugeskr Laeger; 1991 Aug 26; 153(35):2414-6. PubMed ID: 1949240
    [Abstract] [Full Text] [Related]

  • 31. Clinical utility of antilipidemic therapies in chronic renal allograft failure.
    Wanner C, Bartens W, Galle J.
    Kidney Int Suppl; 1995 Dec 26; 52():S60-2. PubMed ID: 8587286
    [Abstract] [Full Text] [Related]

  • 32. Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid--a position paper developed by the European Consensus Panel on HDL-C.
    Chapman MJ, Assmann G, Fruchart JC, Shepherd J, Sirtori C, European Consensus Panel on HDL-C.
    Curr Med Res Opin; 2004 Aug 26; 20(8):1253-68. PubMed ID: 15324528
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. [Prevention and management of complications in nephrotic syndrome].
    Mitarai T.
    Nihon Rinsho; 2004 Oct 26; 62(10):1893-7. PubMed ID: 15500136
    [Abstract] [Full Text] [Related]

  • 36. Probucol for treatment of hyperlipidemia in persistent childhood nephrotic syndrome. Report of a prospective uncontrolled multicenter study.
    Querfeld U, Kohl B, Fiehn W, Minor T, Michalk D, Schärer K, Müller-Wiefel DE.
    Pediatr Nephrol; 1999 Jan 26; 13(1):7-12. PubMed ID: 10100282
    [Abstract] [Full Text] [Related]

  • 37. Lipid changes in the nephrotic syndrome: new insights into pathomechanisms and treatment.
    D'Amico G.
    Klin Wochenschr; 1991 Sep 03; 69(13):618-22. PubMed ID: 1753684
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Dyslipoproteinemia in an inbred rat strain with spontaneous chronic progressive nephrotic syndrome.
    Tarugi P, Nicolini S, Albertazzi L, Calandra S, Salvati P, Ferti C, Patrono C.
    J Lipid Res; 1991 Oct 03; 32(10):1675-87. PubMed ID: 1797947
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.